CD274 and neoplasm: The treatment includes the use of atezolizumab (Tecentriq®) combined with nanoparticle albumin-bound paclitaxel (Abraxane®, nab-paclitaxel) in patients with metastatic TNBC where ≥1% of the tumor area is positive for immune cells expressing programmed cell death-ligand 1 (PD-L1) [58,59].